Evidence map›Paper›PMID 39610500›Full record

ArticleJournal of diabetes and metabolic disorders2024

Maryam Mohammadi-Khanaposhtani, Navid Bakhtiari, Fatemeh Bandarian, Bagher Larijani, Mohammad Mahdavi, Hossein Najafzadehvarzi

Abstract read
In one paragraph

Article in Journal of diabetes and metabolic disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maryam Mohammadi-KhanaposhtaniCellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.ORCID 0000-0001-7664-9664
Navid BakhtiariFaculty of Pharmacy, Islamic Azad University, Ayatollah Amoli Branch, Amol, Iran.
Fatemeh BandarianDiabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Bagher LarijaniEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad MahdaviEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Hossein NajafzadehvarziCellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The Methods: The Results: The obtained results revealed that selected compound Conclusion: In summary, anti-hyperglycemic effects of Graphical abstract:

Indexed as

DiabetesDihydropyrano[3,2-c]quinolineStreptozotocinSynthetic

Identifiers

PMID39610500
PMCPMC11599671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.